Moteur de recherche d’entreprises européennes
Financement de l’UE (3 347 489 €) : Fabrication de cellules tueuses naturelles réactives Hor01/06/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Fabrication de cellules tueuses naturelles réactives
"This project will provide future-oriented translational research training designed to bridge the gap between basic research and applied development of new cell-based therapeutic products by the biotech industry and their clinical use for incurable diseases. This will be done on the example of activated/genetically manipulated natural killer (NK) cells, which are classified as Advanced Therapy Medicinal Products (""ATMPs""), and their use in treatment of cancer refractory to classical therapies. For this we combine experts in NK cell biology supported by bioinformatics, clinical groups pioneering NK cell therapies and biotech companies with NK cell-based portfolios. A student exchange will ensure training in basic, clinical and private sectors. Network-wide training modules organized in summer/winter schools include immunotechnology, business management and intellectual property rights. This will train competences important to translate research findings to personalized medicine. In research we build on information from clinical trials of NK cell-based therapies. We will improve anti-tumor reactivity of NK cells including selection of NK subsets and modulation of NK receptor/ligand interactions. First, this will comprise i) improved donor/recipient combination and NK subsets and ii) modification of NK cells by chimeric antigen receptors (""CAR"") and bispecifc antibody reagents to cross-link NK cells to tumor targets. Second, it will fortify NK cell reactivity by i) blocking ligand interactions of inhibitory receptors (""checkpoint inhibitors"") and ii) defining unknown ligands of activating NK receptors on tumor cells. Third, procedures and NK products in their best combination will be developed by i) evaluation in humanized mouse models, ii) building a GMP-compliant manufacturing process and iii) design of a clinical trial protocol. The project should provide for manufacturing of NK cell-based therapeutic products and their evaluation in clinical trials. "
| FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. | 325 366 € |
| Glycostem-Therapeutics B.V. | 255 374 € |
| Innate Pharma | 182 553 € |
| Institut Pasteur | 262 876 € |
| Irccs Ospedale Policlinico SAN Martino | 258 061 € |
| MEDIZINISCHE HOCHSCHULE HANNOVER | 249 216 € |
| MILTENYI BIOTEC B.V. & Co. KG | 186 912 € |
| MILTENYI BIOTEC GmbH | 62 304 € |
| Medizinische Universitaet Wien | 255 934 € |
| Oslo Universitetssykehus HF | 286 275 € |
| RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG | 249 216 € |
| 260 301 € | |
| 265 227 € | |
| 247 873 € |
https://cordis.europa.eu/project/id/765104
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG e. V. - Financement de l’UE (3 347 489 €) : Fabrication de cellules tueuses naturelles réactives"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
